CG Oncology, Inc. (CGON)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS1569441009
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by CG Oncology, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:28. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 26 Feb 2027 08:00 | -0.73 | — | — | Upcoming |
| 06 Nov 2026 08:00 | -0.81 | -0.64 | +21.0% | Beat |
| 06 Aug 2026 08:00 | -0.64 | -0.90 | -40.1% | Miss |
| 08 May 2026 08:00 | -0.54 | -0.71 | -31.5% | Miss |
| 27 Feb 2026 08:00 | -0.58 | -0.51 | +12.6% | Beat |
| 14 Nov 2025 08:00 | -0.55 | -0.57 | -4.3% | Miss |
| 08 Aug 2025 08:00 | -0.45 | -0.54 | -20.1% | Miss |
| 13 May 2025 08:00 | -0.37 | -0.45 | -20.3% | Miss |
| 28 Mar 2025 07:00 | -0.46 | -0.48 | -4.4% | Miss |
| 12 Nov 2024 08:00 | -0.34 | -0.30 | +11.9% | Beat |
| 08 Aug 2024 06:00 | -0.31 | -0.28 | +11.1% | Beat |
| 09 May 2024 06:00 | -0.15 | -0.36 | -140.0% | Miss |
| 26 Mar 2024 06:00 | -1.00 | -14.42 | -1,342.0% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 4M | +254.7% | -161M | -3,985.0% | -2.08 | -47.5% | -132.5M |
| 2024 | 1.1M | +458.3% | -88M | -7,729.5% | -1.41 | +91.0% | -78.9M |
| 2023 | 204K | +6.8% | -48.6M | -23,827.0% | -15.65 | -33.6% | -45.7M |
| 2022 | 191K | — | -35.4M | -18,556.5% | -11.71 | — | -29.8M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 64.18 | 80.03 | 61.01 | 72.29 | +11.76% | 12,944,412 | |
| Oct 2026 | 70.38 | 71.27 | 59.22 | 64.68 | -8.76% | 19,696,200 | |
| Sep 2026 | 74.74 | 80.63 | 66.01 | 70.89 | -5.68% | 20,530,200 | |
| Aug 2026 | 71.29 | 80.97 | 68.08 | 75.16 | +5.58% | 15,636,900 | |
| Jul 2026 | 70.33 | 75.86 | 67.12 | 71.19 | +0.20% | 20,729,800 | |
| Jun 2026 | 62.00 | 77.00 | 53.21 | 71.05 | +14.06% | 26,202,400 | |
| May 2026 | 65.82 | 75.50 | 59.11 | 62.29 | -6.67% | 19,061,500 | |
| Apr 2026 | 68.22 | 73.56 | 63.03 | 66.74 | -1.39% | 22,861,200 | |
| Mar 2026 | 57.11 | 69.35 | 55.50 | 67.68 | +15.10% | 35,450,800 | |
| Feb 2026 | 51.67 | 60.00 | 48.51 | 58.80 | +12.97% | 15,573,800 | |
| 25 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- What CG Oncology (CGON)'s Third Quarter Earnings Means For Shareholders (opens in a new tab) Simply Wall St. · 10 Nov 2026 13:09
- Guggenheim Maintains Buy on CG Oncology, Lowers Price Target to $89 (opens in a new tab) Benzinga · 09 Nov 2026 11:41
- CG Oncology, Inc. (CGON) Reports Q3 Loss, Beats Revenue Estimates (opens in a new tab) Zacks · 06 Nov 2026 13:55
- CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates (opens in a new tab) 06 Nov 2026 13:15
- CG Oncology Q3 EPS $(0.64) Beats $(0.82) Estimate, Sales $1.604M Beat $643.584K Estimate (opens in a new tab) Benzinga · 06 Nov 2026 09:46
- How Investors May Respond To CG Oncology (CGON) Hiring a CCO Before Potential Bladder Cancer Launch (opens in a new tab) Simply Wall St. · 14 Oct 2026 03:10
- 3 Stocks Call Traders Are Targeting Today (opens in a new tab) Schaeffer's Investment Research · 11 Sep 2026 16:35
- CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run (opens in a new tab) Simply Wall St. · 03 Sep 2026 14:06
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 70.15 USD
- Market cap
- 6.3B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 3.7 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -25.15× | Weak | 14.16× |
| Price / book | 6.32× | Weak | 3.5× |
| Price / sales | 1,016.17× | Weak | 3.33× |
| EV / EBITDA | -20.27× | Weak | 11.19× |
| Free cash flow yield | -1.9% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 54.9% |
| Operating margin | -4,293.5% | Weak | 5.8% |
| Net margin | 0% | Weak | 1.2% |
| Return on equity | -28.3% | Weak | 4.4% |
| Return on assets | -18.6% | Weak | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 176.6% | Good | 10.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.01× | Good | 0.4× |
| Current ratio | 21.7× | Good | 2.64× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow CGON and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.